Fucipan-B

Fucipan-B
7 Jun

Fucipan-B

Anti-Bacterial Agents

  Fucipan®-B cream topical preparation contains two
  active components:
- Fusidic acid which is glycopeptide compound, that
   exerts potent topical antibacterial action.
- When applied topically, fusidic acid is effective
  against staphylococci, streptococci, cornyebacteria,
  neisseria, certain clostridia and bacteroides.
- The antibacterial activity of fusidic acid is not
  diminished by betamethasone.
- Betamethasone is a corticosteroid compound used
  topically for its activity as anti-inflammatory and 
  antipruritic agent.
- Fucipan®-B cream is effective in inflammatory
  dermatoses accompanied by bacterial infection, even 
  refractory condition can often be treated successfully.

Indecation

  Fucipan®-B cream is indicated in inflammatory 
  dermatoses where bacterial infection is present or
  likely to occur.
- Inflammatory dermatoses include atopic eczema,
  discoid eczema, stasis eczema, seborrhoeic dermatitis, 
  contact dermatitis, lichen simple chronicus, psoriasis 
  and discoid lupus erythrematosus.

Dosage & Administration

- Uncovered lesions: Fucipan®-B cream applied 
   2 -3 times daily. 
- Covered lesions: less frequent application may be
   adequate.
- The duration of therapy depends on the indication
  and response of the patient or as directed by the
  physician. 

- Each 100 gram of  Fucipan®-B cream contains :
  Fusidic acid                              2g
  Betamethasone( as valerate) 0.1g

- Hypersensitivity to any component of the product.
- Topical corticosteroids are contraindicated in viral,
   tuberculousis, fungal skin infections, perioral 
   dermatitis, acne rosacea and ulcerative condition.
 

- Topical steroid should not be administered extensively 
  in pregnancy as fetal abnormalities have been seen in 
  animal studies due to systemic absorption. 

- This preparation is generally well tolerated, side effect are infrequent and mild in nature.
- As with other topical corticosteroids, prolong and
  intensive administration may cause local atrophic
  changes of the skin, thinning and dilatation of the
  superficial blood vessels, especially when occlusive
  dressing is used or when skin folds are involved.
- Hypersensitivity reactions have rarely occurred.
- Glaucoma might be the result if the preparation enters
   the eye.

- Long term continuous therapy should be avoided,
  particularly on the face, on flexure, intertrigenous
  areas and in infant and children.
- This medicament should not be applied to broken skin
   or open wound.
- Caution should be observed to avoid any contact of this 
  medicament with the eyes.

Overdose:-
- Significant systemic reactions resulting from improper 
  use or accidental overdose (such as in children) should  
  be managed by taking the necessary supportive 
  measures.

- Tube of 15 g cream .
 

- Store below 30 °C.